News articles about Neurometrix (NASDAQ:NURO) have been trending somewhat negative on Thursday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurometrix earned a media sentiment score of -0.04 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 48.2410282871856 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Neurometrix traded down $0.02, hitting $1.23, during trading on Thursday, MarketBeat reports. 100 shares of the company traded hands, compared to its average volume of 447,662. Neurometrix has a 1 year low of $1.20 and a 1 year high of $3.18.
Neurometrix (NASDAQ:NURO) last announced its quarterly earnings results on Friday, April 20th. The medical device company reported $0.08 earnings per share for the quarter. The company had revenue of $4.94 million during the quarter. Neurometrix had a negative return on equity of 161.28% and a negative net margin of 47.75%.
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.